Navigation Links
Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
Date:9/4/2008

Data Announcements Remain on Schedule with Two Abstracts Accepted for

Presentation, and Large Clinical Data Release in November 2008

BRIDGEWATER, N.J., Sept. 4 /PRNewswire/ -- Aegerion Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced the appointment of Peter L. Garrambone, Jr. to the Company's board of directors.

Peter Garrambone's career includes more than 50 pharmaceutical transactions executed during his 24-year tenure at Pfizer, where he was a senior vice president of Corporate Strategic Planning. At Pfizer, Mr. Garrambone led the company's corporate business development and strategic planning efforts. Most recently, Mr. Garrambone was senior vice president of Business Development for Reliant Pharmaceuticals, which was sold to GlaxoSmithKline for $1.65 billion in the fall of 2007.

"We are fortunate that Peter is joining the board of directors. His extensive strategic and licensing transaction expertise will be invaluable as the company continues the pursuit of its strategic plan with the availability of its important clinical data in November of this year," said David Scheer, Chairman and Co-Founder of Aegerion.

In furtherance of its strategic plan, the Company announced that it had secured additional funding from investors to support ongoing and future clinical trials. The Company will be presenting an abstract at both the American Association for the Study of Liver Disease and American Heart Association Meetings in the fourth quarter of 2008.

Aegerion anticipates receiving the results of three Phase II trials on AEGR 733 before the end of 2008. These trials, comprised of more than 460 patients, are designed to explore the efficacy, safety and tolerability of AEGR 733, Aegerion's lead compound. A Phase III study of AEGR 733 in the orphan population of homozygous familial hypercholesterolemic patients is currently underway.

In addition, Aegerion announced the transition of Jerry Wisler, Co- Founder, CEO and Director of Aegerion, who has left the Company to pursue personal interests.

About Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company focused on the development and commercialization of promising pharmaceuticals to treat cardiovascular and metabolic disease. The Company's primary focus is on hyperlipidemia. Its most advanced products have demonstrated significant LDL lowering activity in human trials and are currently in Phase III and Phase II testing.


'/>"/>
SOURCE Aegerion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
3. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
4. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
5. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
7. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
8. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
9. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 28, 2017 , ... Accreditation Commission for Health Care (ACHC) ... America (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s ... Accreditation University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Getting enough sleep affects much more than ... (NSF), going just 19 hours without sleep can compromise motor reaction time, which can increase ... and Amica Insurance is sharing the following tips from the NSF to help you sleep ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery ... the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, ... patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... People are ... older people. “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa ... Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions ... Grove Foundation implement a Microsoft Dynamics GP solution that integrates to their PointClickCare ... that specializes in long-term care, Brooke Grove now has the capability to achieve ...
Breaking Medicine News(10 mins):